Horan P, Ho IK. 1989. Comparative pharmacological and biochemical
studies between butorphanol and morphine. Pharmacol Biochem Behav
34:847– 854.
Horan P, Ho IK. 1991. The physical dependence liability of butorphanol:
a comparative study with morphine. Eur J Pharmacol 203:387–391.
Imam-Sghiouar N, Laude-Lemaire I, Labas V, Pflieger D, Le Cae ̈r JP,
Caron M, Nabias DK, Joubert-Caron R. 2002. Subproteomics analysis of
phosphorylated proteins: application to the study of B-lymphoblasts from
a patient with Scott syndrome. Proteomics 2:828 – 838.
Jasinski DR, Pvenick JS, Griffith JD, Gorodetzky CW, Cone EJ. 1976.
Progress report from the clinical pharmacology section of the addiction
research center, committee on problems of drug dependence. Proc Natl
Acad Sci USA 112:120.
Jaw SP, Makimura M, Oh KW, Hoskin B, Ho IK. 1994. Involvement of
-opioid receptors in opioid dependence/withdrawal: studies using bu- torphanol. Eur J Pharmacol 257:153–160.
Johnston-Wilson NL, Sims CD, Hoffmann JP, Anderson L, Shore AD,
Torrey EF, Yolken RH. 2000. Disease-specific alterations in frontal
cortex brain proteins in schizophrenia, bipolar disorder, and major de- pressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 5:142–149.
Kosenko E, Llansola M, Montoliu C, Monfort P, Rodrigo R, HernandezViadel M, Erceg S, Sanchez-Perez AM, Felipo V. 2003. Glutamine
synthetase activity and glutamine content in brain: modulation by NMDA
receptors and nitric oxide. Neurochem Int 43:493– 499.
